Developments in the discovery of drugs for spinal muscular atrophy: Successful beginnings and future prospects

Expert Opinion on Drug Discovery

Volumn 6, Issue 8, 2011, Pages 827-837

  Pruss, Rebecca M ^a  

^a Parc Scientifique de Luminy   (France)

Author keywords

Biomarkers; Disease mechanisms; Drug discovery; Neurodegeneration; Neuromuscular disease

Indexed keywords

ACLARUBICIN; AMINOGLYCOSIDE; BUTYRIC ACID; CARBOXYLIC ACID; D 156844; D 157495; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; INDOPROFEN; M 344; OLESOXIME; OLIGONUCLEOTIDE; PANOBINOSTAT; PHENYLBUTYRATE; PRO 105; PTK SMA1; QUINAZOLINE DERIVATIVE; RG 3039; ROMIDEPSIN; SALBUTAMOL; SURVIVAL MOTOR NEURON PROTEIN 2; TC 007; TETRACYCLINE DERIVATIVE; TOBRAMYCIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VANADIC ACID; VOLTAGE DEPENDENT ANION CHANNEL; VORINOSTAT;

CLINICAL TRIAL (TOPIC); DATA BASE; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION; GENETIC STABILITY; HUMAN; MOLECULE; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA SPLICING; SCIENTIFIC LITERATURE; SPINAL MUSCULAR ATROPHY;

EID: 79960514176     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2011.586692     Document Type: Review

References (95)

1. Lefebvre S, Burglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995;80:155-65
2. Liu Q, Dreyfuss G. A novel nuclear structure containing the survival of motor neurons protein. EMBO J 1996;15:3555-65 (Pubitemid 26239768)
3. Liu Q, Fischer U, Wang F, Dreyfuss G. The spinal muscular atrophy disease gene product, SMN, and its associated protein SIP1 are in a complex with spliceosomal snRNP proteins. Cell 1997;90:1013-21 (Pubitemid 27408515)
4. Fischer U, Liu Q, Dreyfuss G. The SMN-SIP1 complex has an essential role in spliceosomal snRNP biogenesis. Cell 1997;90:1023-9 (Pubitemid 27408516)
5. Lefebvre S, Burlet P, Liu Q, et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet 1997;16:265-9 (Pubitemid 27280210)
6. Burghess AHM. When is a deletion not a deletion? When it is converted. Am J Hum Genet 2007;61:9-15
7. Mailman MD, Heinz JW, Papp AC, et al. Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med 2002;4:20-6 (Pubitemid 44698460)
8. Swoboda KJ, Prior TW, Scott CB, et al. Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann Neurol 2005;57:704-12 (Pubitemid 40628859)
9. Lorson CL, Hahnen E, Androphy EJ, Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA 1999;96:6307-11 (Pubitemid 29256661)
10. Lorson CL, Androphy EJ. An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN. Hum Mol Genet 2000;9:259-65
11. Cho S, Dreyfuss G. A degron created by SMN2 exon 7 skipping is a principal contributor to spinal muscular atrophy severity. Genes Dev 2010;24:438-42
12. Chang JG, Hsieh-Li HM, Jong YJ, et al. Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci USA 2001;98:9808-13
13. China Medical College Hospital. US6573300 2003
14. Grzeschik SM, Ganta M, Prior TW, et al. Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells. Ann Neurol 2005;58:194-202 (Pubitemid 41098877)
15. Brichta L, Hofmann Y, Hahnen E, et al. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 2003;12:2481-9 (Pubitemid 37220412)
16. Andreassi C, Angelozzi C, Tiziano FD, et al. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur J Hum Genet 2004;12:59-65 (Pubitemid 38180971)
17. Brahe C, Vitali T, Tiziano FD, et al. Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. Eur J Hum Genet 2005;13:256-9 (Pubitemid 40220572)
18. Hofmann Y, Lorson CL, Stamm S, et al. Htra2-beta 1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2). Proc Natl Acad Sci USA 2000;97:9618-23 (Pubitemid 30650825)
19. Mende Y, Jakubik M, Reissland M, et al. Deficiency of the splicing factor Sfsr10 results in early embryonic in mice and has no impact on full-length SMN/Smn splicing. Hum Mol Gen 2010;19:2154-67
20. Novoyateleva T, Heinrich B, Tang Y, Benderska N. Protein phosphatase 1 binds to the RNA recognition motif of several splicing factors and regulates alternative pre-mRNA processing. Hum Mol Genet 2008;17:52-70
21. Martins de Araujo M, Bonnal S, Hastings ML, et al. Differential 3 splice site recognition of SMN1 and SMN2 transcripts by U2AF and U2 snRNP. RNA 2009;15:515-23
22. Jodelka FM, Ebert AD, Duelli DM, Hastings ML. A feedback loop regulates splicing of the spinal muscular atrophy-modifying gene, SMN2. Hum Mol Genet 2010;19:4906-17
23. Lorson CL, Rindt H, Shababi M. Spinal muscular atrophy: mechanisms and therapeutic strategies. Hum Mol Genet 2010;19:R111-18
24. Andreassi C, Jarecki J, Zhou J, et al. Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum Mol Genet 2001;10:2841-9 (Pubitemid 34026465)
25. Hastings ML, Berniac J, Liu YH, et al. Tetracyclines that promote SMN2 exon 7 splicing as therapeutics for spinal muscular atrophy. Sci Transl Med 2009;1:5ra12
26. Singh NK, Singh NN, Androphy EJ, Singh RN. Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron. Mol Cell Biol 2006;26:1333-46 (Pubitemid 43202560)
27. Williams JH, Schray RC, Patterson CA, et al. Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy. J Neurosci 2009;29:7633-8
28. Hua Y, Sahashi K, Hung G, et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev 2010;24:1634-44
29. Available from http://www.prosensa.eu/technology-and-products/pre- clinicalportfolio
30. Available from http://www.isispharm.com/Pipeline/Therapeutic-Areas/ Neurodegenerative-Disease.htm# ISIS-SMNRx
31. Jarecki J, Chen X, Bernardino A, et al. Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy. Hum Mol Genet 2005;14:2003-18 (Pubitemid 41418036)
32. Pruss RM, Giraudon-Paoli M, Morozova S, et al. Drug discovery and development for spinal muscular atrophy: lessons from screening approaches and future challenes for clinical development Future Med Chem 2010;2:1429-40
33. Vertex Pharmaceuticals, Inc. US7465738; 2008
34. Vertex Pharmaceuticals, Inc. WO2004/112205A2
35. Thurmond J, Butchbach MER, Palomo M, et al. Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy. J Med Chem 2008;51:449-69 (Pubitemid 351252274)
36. Butchbach ME, Singh J, Thorsteinsdottir M, et al. Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy. Hum Mol Genet 2010;19:454-67
37. Singh J, Salcius M, Liu SW, et al. DcpS as a therapeutic target for spinal muscular atrophy. ACS Chem Biol 2008;3:711-22 http://www.repligen.com/ products/pipeline/rgsma
38. Burnett BG, Munoz E, Tandou A, et al. Regulation of SMN protein stability. Mol Cell Biol 2009;29:1107-15
39. Wolstencroft EC, Mattis V, Bajer AA, et al. A non-sequence-specific requirement for SMN protein activity: the role of aminoglycosides in inducing elevated SMN protein levels. Hum Mol Genet 2005;14:1199-210 (Pubitemid 40613908)
40. Heier CR, DiDonato CJ. Translational readthrough by the aminoglycoside geneticin (G418) modulates SMN stability in vitro and improves motor function in SMA mice in vivo. Hum Mol Genet 2009;18:1310-22
41. Chang CW, Hui Y, Elchert B, et al. Pyranmycins, a novel class of aminoglycosides with improved acid stability: the SAR of D-pyranoses on ring III of pyranmycin. Org Lett 2002;4:4603-6
42. Mattis VB, Ebert AD, Fosso MY, et al. Delivery of a read-through inducing compound, TC007, lessens the severity of a spinal muscular atrophy animal model. Hum Mol Genet 2009;18:3906-13
43. Lunn MR, Root DE, Martino AM, et al. Indoprofen upregulated the survival motor neuron protein through a cyclooxygenase-independent mechanism. Chem Biol 2004;11:1489-93 (Pubitemid 39527275)
44. The Spinal Muscular Atrophy Project http://asent.org/22308B47-E7FF-0F41- 24C00CE1DE6EC4AC
45. The trustees of the University of Pennsylvania US2006/0223092A1
46. Wan L, Ottinger E, Cho S, Dreyfuss G. Inactivation of the SMN complex by oxidative stress. Mol Cell 2008;31:244-54 (Pubitemid 352001393)
47. Dreyfuss G, Wan L US2010/0234402A1
48. Zhang HL, Pan F, Hong D, et al. Active transport of the survival motor neuron protein and the role of exon-7 in cytoplasmic localization. J Neurosci 2003;23:6627-37 (Pubitemid 36909889)
49. Rossoll W, Jablonka S, Andreassi C, et al. Smn, the spinal muscular atrophy-determining gene product, modulates axon growth and localization of beta-actin mRNA in growth cones of motoneurons. J Cell Biol 2003;163:801-12 (Pubitemid 37517887)
50. Rossoll W, Bassell GJ. Spinal muscular atrophy and a model for survival of motor neuron protein function in axonal ribonucleoprotein complexes. Results Probl Cell Differ 2009;48:289-326
51. Fallini C, Zhang H, Su Y, et al. The survival of motor neuron (SMN) protein interacts with the mRNA-binding protein HuD and regulates localization of poly (A) mRNA in primary motor neuron axons. J Neurosci 2011;31:3914-25
52. Hahnen E, Forkert R, Marke C, et al. Molecular analysis of candidate genes on chromosome 5q13 in autosomal recessive spinal muscular atrophy: evidence of homozygous deletions of the SMN gene in unaffected individuals. Hum Mol Genet 1995;4:1927-33
53. Oprea GE, Krober S, McWhorter ML, et al. Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy. Science 2008;320:524-7 (Pubitemid 351590664)
54. Bowerman M, Beauvais A, Anderson CL, Kothary R. Rho-kinase inactivation prolongs survival of an intermediate SMA mouse model. Hum Mol Genet 2010;19:1468-78
55. Wen HL, Lin YT, Ting CH, et al. Stathmin, a microtubule-destabilizing protein, is dysregulated in spinal muscular atrophy. Hum Mol Genet 2010;19:1766-78
56. Ebert AD, Yu J, Rose FF, et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009;457:277-80
57. Banks G, Noakes PG. Elucidating the molecular mechanisms that underlie the target control of motoneuron death. Int J Dev Biol 2002;46:551-8 (Pubitemid 36841024)
58. Le TT, Pham LT, Butchbach MER, et al. SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum Mol Genet 2005;14:845-57 (Pubitemid 40403280)
59. Kariya S, Park GH, Maeno-Hikichi Y, et al. Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy. Hum Mol Genet 2008;17:2552-69
60. Murray LM, Comley LH, Thomson D, et al. Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy. Hum Mol Genet 2008;17:949-62 (Pubitemid 351426029)
61. Kong L, Wang X, Choe DW, et al. Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice. J Neurosci 2009;29:842-51
62. Foust KD, Wang X, McGovern VL, et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 2010;28:271-4
63. Michaud M, Arnoux T, Bielli S, et al. Neuromuscular defects and breathing disorders in a new mouse model of spinal muscular atrophy. Neurobiol Dis 2010;38:125-35
64. Park G-H, Maeno-Hikichi Y, Awano T, et al. Reduced suvival of motor neuron (SMN) protein in motor neuronal progenitors functions cell autonomously to cause spinal muscular atrophy in model mice expressing the human centromeric (SMN2) gene. J Neurosci 2010;30:12005-19
65. Rudnik-Schoneborn S, Heller R, Berg C, et al. Congenital heart disease is a feature of severe infantile spinal muscular atrophy. J Med Genet 2008;45:635-8
66. Shababi M, Habibi J, Yang HT, et al. Cardiac defects contribute to the pathology of spinal muscular atrophy models. Hum Mol Genet 2010;19:4059-71
67. Millino C, Fanin M, Vettori A, et al. Different atrophy-hypertrophy transcription pathways in muscles affected by severe and mild spinal muscular atrophy BMC Medicine 2009;7:14-22
68. Tsai LK, Tsai MS, Ting CH, et al. Restoring Bcl-x(L) levels benefits a mouse model of spinal muscular atrophy. Neurobiol Dis 2008;31:361-7
69. Passini MA, Bu J, Roskelley EM, et al. CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J Clin Invest 2010;120:1253-64
70. Valori CF, Ning K, Wyles M, et al. Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci Transl Med 2010;2:35ra42
71. Lorson MA, Spate LD, Prather RS, Lorson CL. Identification and characterization of the porcine (Sus scrofa) survival motor neuron (SMN1) gene: an animal model for therapeutic studies. Dev Dyn 2008;237:2268-78
72. Lorson MA, Spate LD, Samuel MS, et al. Disruption of the Survival Motor Neuron (SMN) gene in pigs using ssDNA. Transgenic Res 2011. [Epub ahead of print]
73. Shababi M, Glascock J, Lorson CL. Combination of SMN trans-splicing and a neurotrophic factor increases the life span and body mass in a severe model of spinal muscular atrophy. Hum Gene Ther 2011;22:135-44
74. Bordet T, Buisson B, Michaud M, et al. Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J Pharmacol Exp Ther 2007;322:709-20 (Pubitemid 47105813)
75. Bordet T, Berna P, Abitbol JL, Pruss RM Olesoxime (TRO19622): A novel mitochondrial-targeted neuroprotective compound. Pharmaceuticals 2010;3:345-68
76. Martin LJ, Adams NA, Pan Y, et al. The mitochondrial permeability transition pore regulates nitric oxide-mediated apoptosis of neurons induced by target deprivation. J Neurosci 2011;31:359-70
77. Rovini A, Carre M, Bordet T, et al. Olesoxime prevents microtubule-targeting drug neurotoxicity: selective preservation of EB comets in differentiated neuronal cells. Biochem Pharmacol 2010;80:884-94
78. Mercuri E, Bertini E, Messina S, et al. Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology 2007;68:51-5 (Pubitemid 46058552)
79. Swoboda KJ, Scott CB, Reyna SP, et al. Phase II open label study of valproic acid in spinal muscular atrophy. PLoS One 2009;4:e5268
80. Lewelt A, Krosschell KJ, Scott C, et al. Compound muscle action potential and motor function in children with spinal muscular atrophy. Muscle Nerve 2010;42:703-8
81. Guidance for Industry Codevelopment of Two or More Unmarketed Investigational Drugs for Use in Combination. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/UCM236669.pdf
82. Zhang ML, Lorson CL, Androphy EJ, Zhou J. An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA. Gene Ther 2001;8:1532-8 (Pubitemid 33061891)
83. Hahnen E, Eyüpoglu IY, Brichta L, et al. In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. J Neurochem 2006;98:193-202 (Pubitemid 43882944)
84. Riessland M, Ackermann B, Forster A, et al. SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. Hum. Mol. Genet 2010;19:1492-1506
85. Avila AM, Burnett BG, Taye AA, et al. Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J Clin Invest 2007;117:659-71 (Pubitemid 46348524)
86. Riessland M, Brichta L, Hahnen E, Wirth B. The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells. Hum Genet 2006;120:101-10
87. Hauke J, Riessland M, Lunde S, et al. Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition. Hum Mol Genet 2009;18:304-17
88. Garbes L, Riessland M, Holker I, et al. LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate. Hum Mol Genet 2009;18:3645-58
89. Tiziano FC, Lomastro R, Pinto AM, et al. Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: relevance for clinical trial design. J Med Genet 2010;47:856-8
90. Mattis VB, Rai R, Wang J, et al. Novel aminoglycosides increase SMN levels in spinal muscular atrophy fibroblasts. Hum Genet 2006;120:589-601 (Pubitemid 44669792)
91. Whitehead Institute for Biomedical Research, Trustees of Columbia University in the City of New York WO2006/050451
92. Stockwell BR, Root DE WO2009/0031435
93. US Department of Health and Human Services, Albany Molecular Research, Saic US2009/0312323A1
94. US Department of Health and Human Services, Saic, Albany Molecular Research US2010/0267712A1
95. Sakla MS, Lorson CL. Induction of full-length survival motor neuron by polyphenol botanical compounds. Hum Genet 2008;122:635-43